Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NYSE:CTLT

Catalent (CTLT) Stock Price, News & Analysis

Catalent logo

About Catalent Stock (NYSE:CTLT)

Advanced Chart
Remove Ads

Key Stats

Today's Range
N/A
50-Day Range
$59.66
$63.48
52-Week Range
N/A
Volume
N/A
Average Volume
1.90 million shs
Market Capitalization
$11.52 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$63.33
Consensus Rating
Hold

Company Overview

Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules. The Pharma and Consumer Health segment offers formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations; and oral, nasal, inhaled, and topical dose forms. This segment also provides clinical supply services through manufacturing, packaging, storage, distribution, and inventory management for small-molecule drugs, protein-based biologics, and cell and gene therapies in clinical trials; and pre-clinical screening, formulation, analytical development, and current good manufacturing practices manufacturing at clinical and commercial scale for softgel capsule, Zydis fast-dissolve tablets, oral solid-dose formats, dry powder inhalers, and nasal delivery devices. The company also offers FlexDirect direct-to-patient and FastChain demand-led clinical supply solutions; fill and finish operations for injectable products; and integrated development and product supply chain solutions. It serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. The company was founded in 1933 and is headquartered in Somerset, New Jersey.

Remove Ads

Catalent Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
42nd Percentile Overall Score

CTLT MarketRank™: 

Catalent scored higher than 42% of companies evaluated by MarketBeat, and ranked 862nd out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Catalent has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 5 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Catalent has received no research coverage in the past 90 days.

  • Read more about Catalent's stock forecast and price target.
  • Earnings Growth

    Earnings for Catalent are expected to grow by 73.08% in the coming year, from $0.78 to $1.35 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Catalent is -28.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Catalent is -28.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Growth Ratio

    Catalent has a PEG Ratio of 2.69. PEG Ratios above 1 indicate that a company could be overvalued.

  • Short Interest

    There is no current short interest data available for CTLT.
  • Dividend Yield

    Catalent does not currently pay a dividend.

  • Dividend Growth

    Catalent does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for CTLT.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Catalent this week, compared to 5 articles on an average week.
  • Search Interest

    2 people have searched for CTLT on MarketBeat in the last 30 days.
Receive CTLT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Catalent and its competitors with MarketBeat's FREE daily newsletter.

CTLT Stock News Headlines

Catalent Announces New Board Appointments
Trump to redistribute trillions of dollars
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.
Novo Holdings Acquires Catalent In $16.5 Bln Cash Deal
See More Headlines

CTLT Stock Analysis - Frequently Asked Questions

Catalent, Inc. (NYSE:CTLT) issued its earnings results on Tuesday, November, 5th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of $0.05 by $0.18. The business's revenue for the quarter was up 4.2% on a year-over-year basis.

Based on aggregate information from My MarketBeat watchlists, some other companies that Catalent investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Netflix (NFLX), JPMorgan Chase & Co. (JPM) and Exxon Mobil (XOM).

Company Calendar

Last Earnings
11/05/2024
Today
4/05/2025
Fiscal Year End
6/30/2025

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NYSE:CTLT
Employees
16,900
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$63.33
High Stock Price Target
$63.50
Low Stock Price Target
$63.00
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
5 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
2.69
Net Income
$-1,043,000,000.00
Pretax Margin
-7.83%

Debt

Sales & Book Value

Annual Sales
$4.38 billion
Price / Cash Flow
24.04
Book Value
$19.91 per share
Price / Book
N/A

Miscellaneous

Free Float
180,949,000
Market Cap
$11.52 billion
Optionable
Optionable
Beta
1.15

Social Links

The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (NYSE:CTLT) was last updated on 4/5/2025 by MarketBeat.com Staff
From Our Partners